KRAS inhibitors, approved
Authors:
- 21 December 2021
- journal article
- editorial
- Published by Springer Nature in Nature Cancer
- Vol. 2 (12) , 1254-1256
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The G protein signaling regulator RGS3 enhances the GTPase activity of KRASScience, 2021
- KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro ExperimentsJournal of Thoracic Oncology, 2021
- Acquired Resistance to KRAS G12C Inhibition in CancerNew England Journal of Medicine, 2021
- Sotorasib for Lung Cancers with KRAS p.G12C MutationNew England Journal of Medicine, 2021
- Kinase-mediated RAS signaling via membraneless cytoplasmic protein granulesCell, 2021
- KRAS G12C Inhibition with Sotorasib in Advanced Solid TumorsNew England Journal of Medicine, 2020
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibitionNature, 2020
- KRAS G12C inhibition produces a driver-limited state revealing collateral dependenciesScience Signaling, 2019
- The ERBB network facilitates KRAS-driven lung tumorigenesisScience Translational Medicine, 2018
- A combinatorial strategy for treating KRAS-mutant lung cancerNature, 2016